PFE - Pfizer Inc.
收市後：
| 前收市價 | 38.89 |
| 開市 | 39.04 |
| 買盤 | 39.11 x 4000 |
| 賣出價 | 39.12 x 1000 |
| 今日波幅 | 38.73 - 39.19 |
| 52 週波幅 | 36.17 - 54.93 |
| 成交量 | |
| 平均成交量 | 24,668,339 |
| 市值 | 220.675B |
| Beta 值 (5 年，每月) | 0.59 |
| 市盈率 (最近 12 個月) | 7.71 |
| 每股盈利 (最近 12 個月) | 5.07 |
| 業績公佈日 | 2023年7月26日 - 2023年7月31日 |
| 遠期股息及收益率 | 1.64 (4.22%) |
| 除息日 | 2023年5月11日 |
| 1 年預測目標價 | 46.80 |
BenzingaChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories
Benzinga Cable Giant CNN Chairman, CEO Chris Licht Moves Out Chris Licht, the news giant CNN's controversial and embattled chairman and CEO, is stepping aside after a very short, turbulent time as CNN's top executive. Licht was appointed CEO a little over a year ago when Warner Bros. Discovery Inc (NASDAQ: WBD) took control of the network. He drew criticism in recent weeks for some of CNN's programming decisions, including a recent town hall with former president and current Republican front-run
BenzingaAnother Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by Promosome accusing their COVID-19 vaccines of infringing a patent related to messenger RNA (mRNA) technology. The small biotechnology firm claims that its scientists, including Nobel laureate Gerald Edelman, who died in 2014, Vincent Mauro, and two colleagues from The Scripps Research Institute, developed a method used in the COVID-19 vaccines. The lawsuit claims that one of the scientist
InvestorPlace3 Undervalued Biotech Stocks to Buy Before They Blast Off
When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That’s not the kind of uncertainty
Insider Monkey15 Best Healthcare Stocks To Buy Now
In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]
InvestorPlaceThe 3 Best Healthcare Stocks to Buy for June 2023
Healthcare stocks have been trailing the market this year. Vanguard’s Health Care ETF (NYSEARCA:VHT) is down 5% on the year, compared with a 10% year-to-date gain in the benchmark S&P 500 index. Investors should view the current slump as an opportunity to take positions in leading healthcare stocks with growth potential. The current dip in healthcare stocks is largely due to investors pulling back after the pandemic when many companies saw their share prices more than double as the quest for a C
BenzingaAmended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
The European Commission (EC) had agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. "The amendment to the existing vaccines supply contract takes into account the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should
- Financial Times
Brussels and Pfizer agree deal to cut supply of Covid vaccines
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
BenzingaFDA Nods to Pfizer's Paxlovid for COVID-19: A Potential $8 Billion Lifesaver in 2023
The FDA has approved Pfizer Inc's (NYSE: PFE) Paxlovid (nirmatrelvir and ritonavir) for mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. The FDA approval is based on safety and efficacy data from the EPIC clinical development program. The Phase 2/3 EPIC-HR study enrolled unvaccinated, non-hospitalized adults aged 18 years and older with confirmed COVID-19 at increased risk of progressing to severe disease. The data s
Insider Monkey14 Best Biotech Stocks To Buy According To Hedge Funds
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
- AASTOCKS
《大行報告》花旗下調輝瑞(PFE.US)目標價至42美元 評級「中性」
花旗發表研究報告指，近日中國每周錄得約6,500萬宗新冠確診個案，超出預期，但新一波染疫能否轉化為輝瑞(PFE.US)的收入來源仍為未知之數，強調今批染疫變異株主要為XBB，屬Omicron的變體，兩者具有相似的致病性。 該行指出，輝瑞新冠口服藥Paxlovid的NRDL緊急核准使用報銷已於2023年4月被撤銷，預期若住院率沒有大幅上升，不太可能會重新獲得緊急使用授權，因此雖然未來出現新變種可能性很高，但仍將今年Paxlovid預測下調，並將公司目標價從50美元降至42美元，評級為「中性」。(gc/k) ~ 阿思達克財經新聞 網址: www.aastocks.com
BenzingaSmall SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M
Pyxis Oncology Inc (NASDAQ: PYXS) agreed to acquire Apexigen Inc (NASDAQ: APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share. Apexigen went public in a blank-check deal just last summer. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million. In February, Apexigen announced evaluating alternatives and reduced its workforce by 55%. "This acquisition uniquely positions Pyxis O
Insider Monkey14 Best Healthcare Dividend Stocks to Buy
In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]
InvestorPlace3 High-Reward Stocks Riding the Healthcare Boom
Healthcare stocks are an attractive prospect right now. Nearly 18% of the U.S. GDP went toward healthcare in 2021, which will only continue growing as the population gets older and sicker. This structural trend should be a rising tide that lifts all boats and will likely play out globally. But which are the best healthcare stocks to buy? There are plenty to choose from. The sector has various players, including insurers, device makers, and pharmaceutical giants. There’s also a new and growing ma
- InvestorPlace
3 Undervalued Pharma Stocks to Buy for High Total Returns
Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors. After an extended bull market, there tends to be a price and time correction phase in various sectors. One secret to successful investing is to identify sectors that have been depressed for an extended period. Stocks in this sector tend to be undervalued, and once sentiments reverse, the rally can be massive. My focus in this column is on undervalued pharma stocks to buy. To
Insider MonkeyBillionaire Jim Simons’ 2023 Portfolio: Top 15 Stock Picks
In this article, we discuss billionaire Jim Simons’ top 15 stock picks in 2023. If you want to see more stocks in this selection, check out Billionaire Jim Simons’ 2023 Portfolio: Top 5 Stock Picks. Managed by Renaissance Technologies, the Medallion Fund stands as one of the world’s most prosperous and enigmatic hedge funds. Established […]
- AASTOCKS
輝瑞嬰兒呼吸道合胞病毒疫苗獲美FDA支持 8月前或批面世
輝瑞(Pfizer)(PFE.US)初生嬰兒免受呼吸道合胞病毒(RSV)疫苗獲美國品和藥物管理局(FDA)支持，為全球首隻相關疫苗獲FDA支持。FDA或於今年8月高峰期之前批准該疫苗可用於孕婦身上，以保護初生嬰兒受感染，在主導該病毒免疫接種中領先同業。 美國FDA委員會所有14名成員均認同該疫苗對孕婦有效，但在安全問題中，10名小組成員認同安全，4名成員指安全數據不充分，認為輝瑞應進一步研究早產風險。 輝瑞目前正與其他藥廠競爭RSV市場，以彌補新冠肺炎疫苗收入大減，RSV市場預計將增長至超過100億美元。 輝瑞周四(18日)收市跌0.7%，消息公布後，盤後股價微升0.08%。(me/m)~ 阿思達克財經新聞 網址: www.aastocks.com
Insider Monkey25 Most Prescribed Medication in the World
In this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see the 10 most prescribed medication in the world. The advancements that the medical field has accomplished over the past century, and especially in recent decades, has […]
- AASTOCKS
輝瑞擬發債籌310億美元以收購Seagen
根據美國證券交易委員會文件，輝瑞(PFE.US)計劃通過發行債券籌集310億美元，以資助收購癌症藥物製造商Seagen(SGEN.US)，為輝瑞自2009年以來最大宗的收購，料收購於今年內或2024年初完成。 據文件，輝瑞將發行於2025年至2063年到期的八批票據，每批債券價值30億美元至60億美元。 輝瑞周三逆市下跌0.8%，Seagen升3.2%。(me/m) ~ 阿思達克財經新聞 網址: www.aastocks.com
BenzingaFDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN) for $43 billion. The debt offering, which would be in eight tranches, is expected to close on May 19. Pfizer expects Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with potential significant growth beyond 2030. Tuesday, Seagen shares came under pressure after the U.S. Federal Trade Commission announced to sue to stop Amgen Inc's
Yahoo FinanceFTC sues to block Amgen's $28B acquisition of Horizon Therapeutics
The regulator said its decision "sends a clear signal to the market" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays.
BenzingaGSK Trims Stake On Consumer Business Spin Off, Raises £804M
GSK Plc (NYSE: GSK) sold 240 million shares of its spun-out consumer healthcare group Haleon Plc (NYSE: HLN) in a move that has raised £804 million for the firm. The offloaded shares are equivalent to up to 2.5% of Haleon's issued share capital. Following the settlement of the placing, GSK will hold 955 million ordinary shares in Haleon, representing approximately 10.3% of its issued share capital. GSK and Pfizer Inc (NYSE: PFE) – which hold a 32% stake in Haleon – have each undertaken not to di
Insider MonkeyRoyalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Call Transcript May 9, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call. I would now like to turn the call over to George Grofik, SVP, Head of Investor Relations and Communications. Please go ahead, sir. George […]
Insider Monkey15 Biggest Immunotherapy Companies in the World
In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]
Insider Monkey20 Most Used Prescription Drugs In The US
In this article, we will take a look at the 20 most used prescription drugs in the US. If you don’t want to get into details, you can comfortably head to the 5 Most Used Prescription Drugs in the US. Prescription drugs have become an important part of healthcare in the US and around the […]